Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by Accountprinceon May 27, 2021 2:01pm
121 Views
Post# 33279277

RE:RE:RE:SP off 30%+ since Seto became CEO

RE:RE:RE:SP off 30%+ since Seto became CEOYou connect a direct line between our share price depreciation and the continuing promotion to CEO of the COO (formerly CFO).  You observe the market depreciating the share price as a direct result of this.  I think to be fair it's a question that should be posed at the upcoming shareholders meeting.  We shareholders have made our investment with the view this holding will appreciate based on the science and technology amongst other things.  If the company possesses any elements (specific personnel) that have the opposite effect then they must answer with vaild reasons why this should be accepted by the owners (including all of us) of the company.

I look forward to hearing you pose this to the meeting and their answer to your question.  I'm guessing I'm not the only one.
<< Previous
Bullboard Posts
Next >>